ArticleNature biomedical engineering2021
Optimization of therapeutic antibodies by predicting antigen specificity from antibody sequence via deep learning.
Article in Nature biomedical engineering, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 159 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
159 citing papers in PubMed, 303 citations in OpenAlex.
- Tokenizing loops of antibodies.mAbs · 2026Article
- Prediction of antibody non-specificity using protein language models and biophysical parameters.mAbs · 2026Article
- Multidimensional maturation of antibody variable domains with machine-learning assistance.mAbs · 2026Article
- Multiobjective VScience advances · 2026Article
- The Evolution of Artificial Intelligence in Antibody Design: From Structure-Based Engineering to Generative Models.Antibodies (Basel, Switzerland) · 2026Review
- Attribution assignment for deep-generative sequence models enables interpretability analysis using positive-only data.PLoS computational biology · 2026Article
- A Synthetic Platform for Antibody Junctional Diversification Beyond Natural Constraints.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- A systematic evaluation framework for universal antibody-antigen binding affinity prediction and candidate recommendation.iScience · 2026Article
- Humanized Anti-PD-1 Antibodies Generated Using The Conditional Kernel-Elastic Autoencoder.bioRxiv : the preprint server for biology · 2026Article
- Functional Parameters of Hybridoma Cells: Methods of Evaluation and Biotechnological Relevance.Antibodies (Basel, Switzerland) · 2026Review
- Multi-objective antibody design and optimization using machine learning.Nature reviews bioengineering · 2026Article
- CD98hc-targeted antibody shuttles for central nervous system delivery with broad cross-species reactivity.Nature biomedical engineering · 2026Article
- Evidence-aware comparison of sequence-centric machine learning for antibody discovery and optimization.Briefings in bioinformatics · 2026Article
- AI-Driven Design Platforms of Next-Generation Antibody Therapeutics.Topics in current chemistry (Cham) · 2026Review
- Multi-omics and artificial intelligence for precision drug discovery and potential clinical applications.Signal transduction and targeted therapy · 2026Review
- Digital twins to accelerate target identification and drug development for immune-mediated disorders.FEBS open bio · 2026Review
- From Single Cells to Silicon: Emerging Technologies Transforming Monoclonal Antibody Discovery.Antibodies (Basel, Switzerland) · 2026Review
- Scaling antibody language models improves structure aware representation for antibody engineering.Communications biology · 2026Article
- The evolution of display technologies for antibody drug discovery.Trends in biotechnology · 2026Review
- MAMMAL - Molecular Aligned Multi-Modal Architecture and Language for biomedical discovery.npj drug discovery · 2026Article
99 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The optimization of therapeutic antibodies is time-intensive and resource-demanding, largely because of the low-throughput screening of full-length antibodies (approximately 1 × 10
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.